AR076968A1 - Compuestos de 1h-imidazo-(4,5-c)-quinolinona - Google Patents
Compuestos de 1h-imidazo-(4,5-c)-quinolinonaInfo
- Publication number
- AR076968A1 AR076968A1 ARP100101965A ARP100101965A AR076968A1 AR 076968 A1 AR076968 A1 AR 076968A1 AR P100101965 A ARP100101965 A AR P100101965A AR P100101965 A ARP100101965 A AR P100101965A AR 076968 A1 AR076968 A1 AR 076968A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyridyl
- alkyl
- alkoxy
- amino
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- -1 hydroxy, amino, amino Chemical group 0.000 abstract 21
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000003545 alkoxy group Chemical group 0.000 abstract 14
- 125000003282 alkyl amino group Chemical group 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 4
- 230000001419 dependent effect Effects 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- IQYPSFAWXDKDBA-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-c]quinolin-2-one Chemical class C1=CC=CC2=C(NC(=O)N3)C3=CN=C21 IQYPSFAWXDKDBA-UHFFFAOYSA-N 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 3
- 125000004076 pyridyl group Chemical group 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000006383 alkylpyridyl group Chemical group 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004983 dialkoxyalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000006377 halopyridyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
- IMNDHOCGZLYMRO-UHFFFAOYSA-N n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1 IMNDHOCGZLYMRO-UHFFFAOYSA-N 0.000 abstract 1
- NCCHARWOCKOHIH-UHFFFAOYSA-N n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1 NCCHARWOCKOHIH-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere al uso de compuestos de 1H-imidazo-[4,5-c]-quinolinona y sales de los mismos en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido, y a la elaboracion de preparaciones farmacéuticas para el tratamiento de estas enfermedades; a compuestos de 1H-imidazo-[4,5-c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido; a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los compuestos de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, en especial, a un ser humano; a las preparaciones farmacéuticas que comprenden un compuesto de 1H-imidazo-[4,5-c]- quinolinona, en especial, para el tratamiento de una enfermedad dependiente de cinasa de proteína y/o de lípido; a compuestos novedosos de 1H-imidazo-[4,5- c]-quinolinona; y a un proceso para la preparacion de los compuestos novedosos de 1 H-imidazo-[4,5-c]-quinolinona. Reivindicacion 1: Un compuesto de la formula (1) en donde X es O o S; Y es CH o N; R1 es piridilo sustituido o insustituido; R2 es hidrogeno o alquilo inferior; R3 es un arilo sustituido o insustituido, o heterociclilo; y R4, R5 y R6 son hidrogeno; o una sal farmacéuticamente aceptable del mismo. Reivindicacion 2: Un compuesto de acuerdo con la reivindicacion 1 en donde: R1 es piridilo que está insustituido o independientemente sustituido por uno, dos o tres sustituyentes seleccionados a partir de halogeno, alquilo insustituido o sustituido, alquenilo insustituido o sustituido, alquinilo insustituido o sustituido, alcoxilo inferior insustituido o sustituido, alcoxi-alquilo inferior insustituido o sustituido, alcoxilo inferior-alcoxilo inferior insustituido o sustituido, cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido, carbamoil-alquilo inferior insustituido o sustituido, mono y di-alquilo inferior-carbamoil-alquilo inferior, cicloamino-carbonilalquilo inferior insustituido o sustituido, heterociclil-carbonil-alquilo inferior insustituido o sustituido, hidroxi-alquilo inferior insustituido o sustituido, carboxi-alquilo inferior insustituido o sustituido, halo-alquilo inferior, hidroxi-carbonil-alquilo inferior, pirazinilo insustituido o sustituido, hidroxilo, amino, amino sustituido por mono- o di-alquilo inferior, piperazinilo insustituido o sustituido, amino sustituido por N-alquilo inferior-N-alcoxilo inferior-alquilo inferior, alcoxilo inferior-alquilo inferior-carbonil-amino, oxopiperazinilo, cicloamino insustituido o sustituido, amino sustituido por N-alquilo inferior-N-hidroxi-alquilo inferior o una sal farmacéuticamente aceptable del mismo. Reivindicacion 6: Un compuesto de acuerdo con cualquiera de las reivindicaciones anteriores, en donde R3 se selecciona a partir de fenilo; hidroxi-fenilo; metoxifenilo; etoxi-fenilo; metoxi-etoxi-fenilo; metoxi-(metoxi-etoxi)-fenilo, hidroxi-alcoxi-fenilo; halo-hidroxi-fenilo; hidroxi-halo-alquil-fenilo; 2,2-difluoro-benzo-[1,3]-dioxolo; bencen-sulfonamida; 3-(pirrolidin-1-sulfonil)-fenilo; N-(fen-3-il)-metan-sulfonamida; N-metil-N-fen-3-il- metan-sulfonamida; alquil-sulfonil-fenilo; benzamida; N-metil-benzamida; N,N-dimetil-benzamida; pirazol-fenilo; imidazol-fenilo; piridilo; alquil-piridilo; alcoxi-piridilo; etoxi-piridilo; propoxi-piridilo; cicloalquil-alcoxi-piridilo; alcoxi-alquil-piridilo; alcoxi-alcoxi-piridilo; benciloxi-alcoxi-piridilo; hidroxi-alquil-piridilo; alquil-sulfonil-piridilo; hidroxi-alcoxi-piridilo; alcoxi-carbonil-piridilo; amino-piridilo; alquilamino-piridilo; dialquil-amino-piridilo; cicloamino-piridilo; (cianoalquilo inferior)-piridinilo; (ciano-cicloalquilo inferior)-piridinilo; hidroxi-alquilo-amino-piridilo; amino-halo-alquilo inferior-piridilo; halo-alquil-piridinilo; halo-piridilo; halo-alcoxi-piridilo; carbamoil-piridilo; carbamoilo sustituido por alquilo; piperazinil-piridilo; N-alquil-piperazinil-piridilo; alquil-sulfonamido-piridilo; dialquil-sulfonamido-piridilo; (alquil-sulfonamido)-(alquil)-piridilo; dialquil-sulfonamido-(alquil)-piridilo; 3H-tetrazol-5-il-piridilo; (alcoxi)-(alquil-carbonil-amino)-piridilo; (alcoxi)-(alquil-carbonil-N-alquil-amino)-piridilo; (alcoxi)-(nitro)-piridilo; (alcoxi)-(amino)-piridilo; (alcoxi)-(alquil-amino-carbonil)-piridilo; (alcoxi)-(hidroxi-carbonil)-piridilo; N,N-di-alquilo inferior-amino-alcoxilo inferior; (N,N-dimetil-amino-propoxi)-piridilo; (alquil)-(alcoxi)-piridilo; (dialcoxi-alquil)-(alcoxi)-piridilo; (alcoxi-alquil)-(alcoxi )-piridilo; (hidroxi-alquil)-alquil-amino)-piridilo; (alquil)-(alquil-amino)-piridilo; (habo)-(alquil-amino)-piridilo; (halo-alquil)-(alquil-amino)-piridilo; (habo-alquil)-(amino)-piridilo; (hidroxi-alquil)-(alcoxi)-piridilo; (hidroxi-alquil)-(amino)-piridilo; (alcoxi-alquil)-(amino)-piridilo; (alquil)-(alcoxi-alcoxi)-piridilo; (alcoxi-alquil)-(alquil-amino)-piridilo; (amino)-(alquil-amino-carbonil)-piridilo; pirimidinilo; alquilo inferior-amino-pirimidinilo; di-alquilo Inferior-amino-pirimidinilo; alcoxi-pirimidinilo; di-alcoxilo inferior-pirimidinilo; (alquil-amino)-(alcoxi)-pirimidinilo; 1H-pirrolo-[2,3-b]-piridinilo; 1-metil-1H-pirrolo-[2,3-b]-piridinilo; pirazinilo; pirazolilo; pirazolilo sustituido; quinolinilo; 2-oxo-2,3-dihidro-1H-indol-5-ilo; 1-metil-2,3-dihidro-1H-indol-5-ilo; 1H-imidazo-[4,5-b]-piridin-2(3H)-on-6-ilo; 3H-imidazo-[4,5-b]-piridin-6-ilo; 3H-[1,2,3]-triazolo-[4,5-b]-piridin-6-ilo; imidazo-[1,2-a]-piridinilo, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21783609P | 2009-06-04 | 2009-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076968A1 true AR076968A1 (es) | 2011-07-20 |
Family
ID=42670520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101965A AR076968A1 (es) | 2009-06-04 | 2010-06-03 | Compuestos de 1h-imidazo-(4,5-c)-quinolinona |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100311714A1 (es) |
| EP (1) | EP2438063A1 (es) |
| JP (1) | JP2012528829A (es) |
| CN (1) | CN102803259A (es) |
| AR (1) | AR076968A1 (es) |
| TW (1) | TW201100420A (es) |
| UY (1) | UY32691A (es) |
| WO (1) | WO2010139747A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2523957A1 (en) * | 2010-01-12 | 2012-11-21 | F. Hoffmann-La Roche AG | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| WO2012077031A1 (en) | 2010-12-06 | 2012-06-14 | Piramal Life Sciences Limited | Substituted imidazoquinoline derivatives |
| JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| WO2013016411A1 (en) * | 2011-07-28 | 2013-01-31 | Garry Robert Smith | Novel fluorinated cyclic sulfamides exhibiting neuroprotective action and their method of use |
| CN103030637A (zh) * | 2011-10-10 | 2013-04-10 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
| US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| CN111689963A (zh) | 2015-04-02 | 2020-09-22 | 默克专利股份公司 | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201604182D0 (en) * | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| BR112019007594A2 (pt) | 2016-10-13 | 2019-07-02 | Loyola University Of Chicago | método para bloquear a transmissão do parasita da malária |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| CN116574099A (zh) * | 2019-09-23 | 2023-08-11 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
| CA2735932C (en) * | 2008-09-30 | 2013-07-09 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 EP EP10720790A patent/EP2438063A1/en not_active Withdrawn
- 2010-06-02 JP JP2012513620A patent/JP2012528829A/ja active Pending
- 2010-06-02 WO PCT/EP2010/057746 patent/WO2010139747A1/en not_active Ceased
- 2010-06-02 CN CN2010800244631A patent/CN102803259A/zh active Pending
- 2010-06-02 US US12/792,187 patent/US20100311714A1/en not_active Abandoned
- 2010-06-03 TW TW099118010A patent/TW201100420A/zh unknown
- 2010-06-03 AR ARP100101965A patent/AR076968A1/es unknown
- 2010-06-04 UY UY0001032691A patent/UY32691A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102803259A (zh) | 2012-11-28 |
| UY32691A (es) | 2011-01-31 |
| US20100311714A1 (en) | 2010-12-09 |
| EP2438063A1 (en) | 2012-04-11 |
| JP2012528829A (ja) | 2012-11-15 |
| TW201100420A (en) | 2011-01-01 |
| WO2010139747A1 (en) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076968A1 (es) | Compuestos de 1h-imidazo-(4,5-c)-quinolinona | |
| CA2908776C (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas | |
| RU2519673C2 (ru) | Комбинации ингибитора hsp90 | |
| CA2817317C (en) | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ES2873959T3 (es) | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer | |
| AU2017203474B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| US20150290197A1 (en) | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | |
| CA3045465A1 (en) | Preservation of immune response during chemotherapy regimens | |
| CA2978807A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| AU2017208948A1 (en) | Compounds and compositions for the treatment of cryptosporidiosis | |
| US20240343718A1 (en) | Treatment of neurological disorders | |
| NZ712033B2 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |